Expansion Therapeutics

Expansion Therapeutics is a biotechnology company focused on developing oral medicines for severe RNA-mediated diseases, particularly neurodegenerative disorders. They are utilizing a proprietary platform called SMiRNA™ which aims to identify and modulate druggable RNA structures to deliver oral medicines. This platform leverages patient genetics and deep informatic analysis to identify disease-driving RNA structures and then screens these against their proprietary libraries for small molecules that can bind and modulate these structures.

Expansion Therapeutics' pipeline includes programs targeting myotonic dystrophy type 1, amyotrophic lateral sclerosis, frontotemporal dementia, and tauopathies. They are committed to developing treatments for diseases with limited or no current therapeutic options, and their research is based on groundbreaking research from the laboratory of Matthew D. Disney, Ph.D., at Scripps Research.

Expansion Therapeutics does not explicitly mention job flexibility on their website. However, they have offices in Boston, MA, Jupiter, FL, and Cambridge, MA, suggesting potential for remote or hybrid work arrangements, depending on the specific role and team.

Expansion Therapeutics is a biotechnology company dedicated to developing transformative oral medicines that target RNA for the treatment of severe RNA-mediated diseases, particularly neurodegenerative disorders. The company leverages its proprietary SMiRNA™ platform, which focuses on identifying druggable RNA structures to create small molecule drugs capable of modulating RNA function. Their mission is to improve the lives of patients suffering from debilitating neurological diseases by providing novel therapies that address the root cause of these conditions, offering hope for a cure.

Expansion Therapeutics promotes a culture of innovation, collaboration, and patient-centricity. The company's website emphasizes its commitment to developing transformative oral medicines for severe RNA-mediated diseases, and its team is described as being in relentless pursuit of game-changing solutions in human health. This suggests a culture that values scientific excellence, teamwork, and a shared passion for improving patient outcomes. The company's focus on structured RNA targets and its proprietary SMiRNA™ platform further highlights its commitment to groundbreaking research and development.

Expansion Therapeutics is committed to creating an inclusive and equitable workplace that values diversity of thought and experience. They are dedicated to building a culture where all employees feel respected, supported, and empowered to contribute their unique perspectives. This commitment is reflected in their efforts to attract, develop, and retain a diverse workforce, promote equity in all aspects of employment, and foster an inclusive environment that celebrates the contributions of all employees.